Lilly gets 6-month Cymbalta marketing extension

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug.

Lilly said marketing exclusivity on Cymbalta will now expire in December 2013, which means generic versions of the drug will not be approved until then.

The extension could mean more than a billion dollars in sales for the Indianapolis drug maker. 

The drugmaker said the Food and Drug Administration had determined that Cymbalta meets requirements for a pediatric exclusivity extension even though Cymbalta is not approved for use in children.

Cymbalta is approved for patients 18 and older, and Lilly said it does not plan to try to get the drug approved for use in children. But the FDA's finding still gives the company another six months to sell Cymbalta without generic competition.

U.S. sales of Cymbalta totaled $1.77 billion in the fourth quarter of 2011 and the first quarter of 2012. That was about three-quarters of all worldwide sales of the drug.

Shares of Eli Lilly fell 34 cents, to $42.51 each, in morning trading Friday. Its shares hit a 52-week high of $43.31 on Tuesday.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ